Literature DB >> 15512883

ALSFRS-R.

Paul H Gordon1, Robert G Miller, Dan H Moore.   

Abstract

The ALSFRS-R is an attractive primary outcome measure in clinical trials of ALS because it is validated, easy to administer, minimizes dropout, reduces cost, and correlates with survival. Unlike the other standard outcome measures currently employed, the ALSFRS-R is also a measure of global function.

Mesh：

Year:  2004        PMID： 15512883     DOI： 10.1080/17434470410019906

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler Other Motor Neuron Disord        ISSN： 1466-0822


  24 in total

Review 1.  Amyotrophic Lateral Sclerosis: An update for 2013 Clinical Features, Pathophysiology, Management and Therapeutic Trials.

Authors:  Paul H Gordon
Journal:  Aging Dis       Date:  2013-10-01       Impact factor: 6.745

Review 2.  Prognostic factors for the course of functional status of patients with ALS: a systematic review.

Authors:  Huub Creemers; Hepke Grupstra; Frans Nollet; Leonard H van den Berg; Anita Beelen
Journal:  J Neurol       Date:  2014-11-11       Impact factor: 4.849

3.  ALS Multicenter Cohort Study of Oxidative Stress (ALS COSMOS): study methodology, recruitment, and baseline demographic and disease characteristics.

Authors:  Hiroshi Mitsumoto; Pam Factor-Litvak; Howard Andrews; Raymond R Goetz; Leslie Andrews; Judith G Rabkin; Martin McElhiney; Jeri Nieves; Regina M Santella; Jennifer Murphy; Jonathan Hupf; Jess Singleton; David Merle; Mary Kilty; Daragh Heitzman; Richard S Bedlack; Robert G Miller; Jonathan S Katz; Dallas Forshew; Richard J Barohn; Eric J Sorenson; Bjorn Oskarsson; J Americo M Fernandes Filho; Edward J Kasarskis; Catherine Lomen-Hoerth; Tahseen Mozaffar; Yvonne D Rollins; Sharon P Nations; Andrea J Swenson; Jeremy M Shefner; Jinsy A Andrews; Boguslawa A Koczon-Jaremko
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2014-02-24       Impact factor: 4.092

Review 4.  Clinical Measures of Disease Progression in Amyotrophic Lateral Sclerosis.

Authors:  Seward B Rutkove
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

5.  Blood levels of trace metals and amyotrophic lateral sclerosis.

Authors:  Tracy L Peters; John D Beard; David M Umbach; Kelli Allen; Jean Keller; Daniela Mariosa; Dale P Sandler; Silke Schmidt; Fang Fang; Weimin Ye; Freya Kamel
Journal:  Neurotoxicology       Date:  2016-04-13       Impact factor: 4.294

6.  The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis.

Authors:  Merit Cudkowicz; Michael E Bozik; Evan W Ingersoll; Robert Miller; Hiroshi Mitsumoto; Jeremy Shefner; Dan H Moore; David Schoenfeld; James L Mather; Donald Archibald; Mary Sullivan; Craig Amburgey; Juliet Moritz; Valentin K Gribkoff
Journal:  Nat Med       Date:  2011-11-20       Impact factor: 53.440

Review 7.  The role of the neuromuscular medicine and physiatry specialists in the multidisciplinary management of neuromuscular disease.

Authors:  Craig M McDonald; William M Fowler
Journal:  Phys Med Rehabil Clin N Am       Date:  2012-08       Impact factor: 1.784

8.  Tollgate-based progression pathways of ALS patients.

Authors:  Özden O Dalgıç; F Safa Erenay; Kalyan S Pasupathy; Osman Y Özaltın; Brian A Crum; Mustafa Y Sir
Journal:  J Neurol       Date:  2019-01-25       Impact factor: 4.849

9.  Association Between Dietary Intake and Function in Amyotrophic Lateral Sclerosis.

Authors:  Jeri W Nieves; Chris Gennings; Pam Factor-Litvak; Jonathan Hupf; Jessica Singleton; Valerie Sharf; Björn Oskarsson; J Americo M Fernandes Filho; Eric J Sorenson; Emanuele D'Amico; Ray Goetz; Hiroshi Mitsumoto
Journal:  JAMA Neurol       Date:  2016-12-01       Impact factor: 18.302

10.  Serum caspase-9 levels are increased in patients with amyotrophic lateral sclerosis.

Authors:  Joanna Iłżecka
Journal:  Neurol Sci       Date:  2011-11-03       Impact factor: 3.307
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.